Loading...

Diane Havlir, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address1001 Potrero Ave
San Francisco CA 94110
Phone415-476-4082 ext. 400
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Case Western Reserve University, Cleveland, OHFellow1990Fellowship, Infectious Diseases
    University of California, San Francisco, San Francisco, CAResidency 1987Internal Medicine Residency
    Duke University Medical School, Durham, NCM.D.1984Medicine
    St. Olaf College, Northfield, MinnesotaB.A.1980Chemistry/Biology
    Collapse Awards and Honors
    Duke University Medical School2017Duke Distinguished Alumni Award
    San Francisco General Hospital Foundation2015Heroes and Hearts Award
    Project Inform2014Thomas M Kelley Leadership Award
    University of California, San Francisco2014Chancellors Award for the Advancement of Women
    St. Olaf College2013Alumni Achievement Award
    University of California, San Francisco2014Pathways Mentorship Award
    Infectious Diseases Society of America2012Joseph E. Smadel Infectious Diseases Society of America Award
    International AIDS Conference2012United States Co-Chair for XIX International AIDS Conference
    Vanity Fair2012Vanity Fair Hall of Fame, “Pioneering leader in the fight against AIDS”
    University of California, San Francisco2010AIDS Research Institute Award for Outstanding Mentoring
    International AIDS Conference2010Scientific Chair for XVIII International AIDS Conference, Vienna
    University of California, San Francisco2009Pediatric Mentorship Award

    Collapse Overview 
    Collapse Overview
    The goal of my research is to develop therapeutic strategies to improve the lives of persons living with HIV, to reduce the global burden of HIV, and to advance public health in East Africa. Antiretroviral therapy is one of the greatest successes in medicine, yet we have not fully used it to eliminate HIV or tuberculosis (TB). My current areas of focus include 1) optimal HIV treatment approaches in the US with special attention to vulnerable populations in San Francisco, 2) optimal treatment strategies for HIV and TB, including new TB drug agents, 3) strategies to reduce the burden of HIV and malaria in children and pregnant women, and 4) testing of innovative approaches to early treatment of HIV using a community-based multi-disease approach following 320,000 persons in Uganda and Kenya to benefit the overall health, education and economics of communities in East Africa in the SEARCH study.


    Collapse Research 
    Collapse Research Activities and Funding
    Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden
    NIH/NIAID R01AI125000Dec 14, 2016 - Nov 30, 2021
    Role: Principal Investigator
    Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)
    NIH/NIAID U01AI099959Jul 1, 2012 - Jun 30, 2017
    Role: Principal Investigator
    Novel Strategies to Prevent Malaria and Improve Maternal-Child Health in Africa
    NIH/NICHD P01HD059454Aug 1, 2008 - Jun 30, 2018
    Role: Principal Investigator
    San Francisco Bay Clinical Trials Unit
    NIH/NIAID UM1AI069496Mar 2, 2007 - Nov 30, 2020
    Role: Co-Principal Investigator
    UCSF HIV Clinical Trials Unit
    NIH/NIAID UM1AI069502Jan 1, 2007 - May 30, 2014
    Role: Principal Investigator
    UCSF HIV Clinical Trials Unit
    NIH/NIAID U01AI069502Jan 1, 2007 - Nov 30, 2013
    Role: Principal Investigator
    Clinical Studies of Interactions Between HIV and Malaria
    NIH/NIAID U01AI062677Sep 30, 2004 - May 31, 2010
    Role: Principal Investigator
    Training in HIV Translational Research
    NIH/NIAID T32AI060530Jul 1, 2004 - Jul 31, 2021
    Role: Principal Investigator
    Therapeutic Strategies for HIV Disease
    NIH/NIAID K24AI051982Apr 15, 2002 - Mar 31, 2014
    Role: Principal Investigator
    Center for AIDS Research
    NIH/NIAID P30AI036214Apr 1, 1994 - Mar 31, 2023
    Role: Co-Investigator
    UCSF-Gladstone Center for AIDS Research
    NIH/NIAID P30AI027763Sep 30, 1988 - Aug 31, 2022
    Role: Co-Investigator
    ADULT AIDS CLINICAL TRIALS UNIT
    NIH/NIAID U01AI027663Jun 30, 1986 - Dec 31, 2006
    Role: Principal Investigator
    SAN DIEGO AIDS CLINICAL TRIAL UNIT
    NIH/NIAID U01AI027670Jun 30, 1986 - Dec 31, 2006
    Role: Co-Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH. Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clin Infect Dis. 2018 Sep 14. PMID: 30219823.
      View in: PubMed
    2. Ayieko J, Chamie G, Balzer L, Kwarisiima D, Kabami J, Sang N, Cohen CR, Bukusi EA, Clark TD, Plenty A, Charlebois ED, Petersen M, Kamya M, Havlir D, Ruel T. Mobile, Population-Wide, Hybrid HIV Testing Strategy Increases Number of Children Tested in Rural Kenya and Uganda. Pediatr Infect Dis J. 2018 Sep 07. PMID: 30199482.
      View in: PubMed
    3. Ayieko J, Brown L, Anthierens S, Van Rie A, Getahun M, Charlebois ED, Petersen ML, Clark TD, Kamya MR, Cohen CR, Bukusi EA, Havlir DV, Camlin CS. "Hurdles on the path to 90-90-90 and beyond": Qualitative analysis of barriers to engagement in HIV care among individuals in rural East Africa in the context of test-and-treat. PLoS One. 2018; 13(8):e0202990. PMID: 30161172.
      View in: PubMed
    4. Shade SB, Osmand T, Luo A, Aine R, Assurah E, Mwebaza B, Mwai D, Owaraganise A, Mwangwa F, Ayieko J, Black D, Brown LB, Clark TD, Kwarisiima D, Thirumurthy H, Cohen CR, Bukusi EA, Charlebois ED, Balzer L, Kamya MR, Petersen ML, Havlir DV, Jain V. Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the search study. AIDS. 2018 Aug 20. PMID: 30134294.
      View in: PubMed
    5. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018 Jul 28; 392(10144):312-358. PMID: 30032975.
      View in: PubMed
    6. Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018 Jul; 15(7):e1002606. PMID: 30016328.
      View in: PubMed
    7. Jakubowski A, Snyman K, Kwarisiima D, Sang N, Burger R, Balzer L, Clark T, Chamie G, Shade S, Cohen C, Bukusi E, Charlebois E, Kamya M, Petersen M, Havlir D, Thirumurthy H. High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial. PLoS One. 2018; 13(6):e0198912. PMID: 29944678.
      View in: PubMed
    8. Ayieko J, Petersen ML, van Rie A, Wafula E, Opudo W, Clark TD, Kamya MR, Balzer LB, Cohen CR, Bukusi EA, Charlebois ED, Havlir DV. Effect of a Patient-Centered Phone Call by a Clinical Officer at Time of HIV Testing on Linkage to Care in Rural Kenya. Open Forum Infect Dis. 2018 Jun 01; 5(6):ofy126. PMID: 29977971.
      View in: PubMed
    9. Koss CA, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Balzer LB, Plenty A, Sang N, Kabami J, Ruel TD, Black D, Camlin CS, Cohen CR, Bukusi EA, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV. Early Adopters of HIV Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda. Clin Infect Dis. 2018 May 05. PMID: 29741594.
      View in: PubMed
    10. Currier JS, Havlir DV. CROI 2018: Complications of HIV Infection and Antiretroviral Therapy. Top Antivir Med. 2018 May; 26(1):22-29. PMID: 29727294.
      View in: PubMed
    11. Sattler FR, Chelliah D, Wu X, Sanchez A, Kendall MA, Hogg E, Lagat D, Lalloo U, Veloso V, Havlir DV, Landay A. Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells. Pathog Immun. 2018; 3(1):46-62. PMID: 29770360.
      View in: PubMed
    12. Chamie G, Schaffer EM, Ndyabakira A, Emperador DM, Kwarisiima D, Camlin CS, Havlir DV, Kahn JG, Kamya MR, Thirumurthy H. Comparative effectiveness of novel non-monetary incentives to promote HIV testing: a randomized trial. AIDS. 2018 Apr 19. PMID: 29683850.
      View in: PubMed
    13. Scheer S, Hsu L, Schwarcz S, Pipkin S, Havlir D, Buchbinder S, Hessol NA. Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the "Getting to Zero" Era. Clin Infect Dis. 2018 Mar 19; 66(7):1027-1034. PMID: 29099913.
      View in: PubMed
    14. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 Mar 14. PMID: 29547881.
      View in: PubMed
    15. Clemenzi-Allen A, Geng E, Christopoulos K, Hammer H, Buchbinder S, Havlir D, Gandhi M. Degree of Housing Instability Shows Independent "Dose-Response" With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus. Open Forum Infect Dis. 2018 Mar; 5(3):ofy035. PMID: 29577059.
      View in: PubMed
    16. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 Mar 05; 217(6):964-972. PMID: 29272443.
      View in: PubMed
    17. Chamie G, Kato-Maeda M, Emperador DM, Wandera B, Mugagga O, Crandall J, Janes M, Marquez C, Kamya MR, Charlebois ED, Havlir DV. Spatial overlap links seemingly unconnected genotype-matched TB cases in rural Uganda. PLoS One. 2018; 13(2):e0192666. PMID: 29438413.
      View in: PubMed
    18. Perriat D, Balzer L, Hayes R, Lockman S, Walsh F, Ayles H, Floyd S, Havlir D, Kamya M, Lebelonyane R, Mills LA, Okello V, Petersen M, Pillay D, Sabapathy K, Wirth K, Orne-Gliemann J, Dabis F. Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa. J Int AIDS Soc. 2018 Jan; 21(1). PMID: 29314658.
      View in: PubMed
    19. Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, Kwariisima D, Clark TD, Petersen ML, Charlebois ED, Kamya MR, Chamie G, Havlir DV, Marquez C. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr. 2017 12 15; 76(5):e115-e117. PMID: 28885271.
      View in: PubMed
    20. Camlin CS, Charlebois ED, Geng E, Semitala F, Wallenta J, Getahun M, Kampiire L, Bukusi EA, Sang N, Kwarisiima D, Clark TD, Petersen ML, Kamya MR, Havlir DV. Redemption of the "spoiled identity:" the role of HIV-positive individuals in HIV care cascade interventions. J Int AIDS Soc. 2017 Dec; 20(4). PMID: 29210185.
      View in: PubMed
    21. Semitala FC, Camlin CS, Wallenta J, Kampiire L, Katuramu R, Amanyire G, Namusobya J, Chang W, Kahn JG, Charlebois ED, Havlir DV, Kamya MR, Geng EH. Understanding uptake of an intervention to accelerate antiretroviral therapy initiation in Uganda via qualitative inquiry. J Int AIDS Soc. 2017 Dec; 20(4). PMID: 29206357.
      View in: PubMed
    22. Mwangwa F, Chamie G, Kwarisiima D, Ayieko J, Owaraganise A, Ruel TD, Plenty A, Tram KH, Clark TD, Cohen CR, Bukusi EA, Petersen M, Kamya MR, Charlebois ED, Havlir DV, Marquez C. Gaps in the Child Tuberculosis Care Cascade in 32 Rural Communities in Uganda and Kenya. J Clin Tuberc Other Mycobact Dis. 2017 Dec; 9:24-29. PMID: 29291251.
      View in: PubMed
    23. Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018 Mar; 5(3):e146-e154. PMID: 29174084.
      View in: PubMed
    24. Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 Nov 15; 216(8):1008-1017. PMID: 28968782.
      View in: PubMed
    25. Conroy AL, McDonald CR, Gamble JL, Olwoch P, Natureeba P, Cohan D, Kamya MR, Havlir DV, Dorsey G, Kain KC. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol. 2017 12; 217(6):684.e1-684.e17. PMID: 29031892.
      View in: PubMed
    26. Roh ME, Shiboski S, Natureeba P, Kakuru A, Muhindo M, Ochieng T, Plenty A, Koss CA, Clark TD, Awori P, Nakalambe M, Cohan D, Jagannathan P, Gosling R, Havlir DV, Kamya MR, Dorsey G. Protective effect of indoor residual spraying of insecticide on preterm birth among pregnant women with HIV in Uganda: A secondary data analysis. J Infect Dis. 2017 Oct 06. PMID: 29029337.
      View in: PubMed
    27. Kapisi J, Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Ssekitoleko R, Olwoch P, Ategeka J, Nayebare P, Clark TD, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G, Gaw SL. Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J. 2017 Oct 05; 16(1):400. PMID: 28982374.
      View in: PubMed
    28. Brown LB, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Black D, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV. Predictors of Retention in HIV Care Among Youth (15-24) in a Universal Test-and-Treat Setting in Rural Kenya. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):e15-e18. PMID: 28394821.
      View in: PubMed
    29. Geng EH, Havlir DV. The science of rapid start-From the when to the how of antiretroviral initiation. PLoS Med. 2017 Jul; 14(7):e1002358. PMID: 28742819.
      View in: PubMed
    30. Kwarisiima D, Kamya MR, Owaraganise A, Mwangwa F, Byonanebye DM, Ayieko J, Plenty A, Black D, Clark TD, Nzarubara B, Snyman K, Brown L, Bukusi E, Cohen CR, Geng EH, Charlebois ED, Ruel TD, Petersen ML, Havlir D, Jain V. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya. J Int AIDS Soc. 2017 07 21; 20(Suppl 4):21673. PMID: 28770596.
      View in: PubMed
    31. Natureeba P, Kakuru A, Muhindo M, Ochieng T, Ategeka J, Koss CA, Plenty A, Charlebois ED, Clark TD, Nzarubara B, Nakalembe M, Cohan D, Rizzuto G, Muehlenbachs A, Ruel T, Jagannathan P, Havlir DV, Kamya MR, Dorsey G. Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women. J Infect Dis. 2017 Jul 01; 216(1):29-35. PMID: 28329368.
      View in: PubMed
    32. Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, Kamya M, Havlir D. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA. 2017 Jun 06; 317(21):2196-2206. PMID: 28586888.
      View in: PubMed
    33. Currier JS, Havlir DV. CROI 2017: Complications and Comorbidities of HIV Disease and Its Treatment. Top Antivir Med. 2017 May/Jun; 25(2):77-83. PMID: 28598792.
      View in: PubMed
    34. Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, Cohan D, Okiring J, Charlebois ED, Kamya MR, Havlir DV. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda. J Acquir Immune Defic Syndr. 2017 Mar 01; 74(3):279-284. PMID: 27828878.
      View in: PubMed
    35. Prahl M, Jagannathan P, McIntyre TI, Auma A, Wamala S, Nalubega M, Musinguzi K, Naluwu K, Sikyoma E, Budker R, Odorizzi P, Kakuru A, Havlir DV, Kamya MR, Dorsey G, Feeney ME. Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis. 2017; 4(1):ofx022. PMID: 28480292.
      View in: PubMed
    36. Pilcher CD, Ospina-Norvell C, Dasgupta A, Jones D, Hartogensis W, Torres S, Calderon F, Demicco E, Geng E, Gandhi M, Havlir DV, Hatano H. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr. 2017 Jan 01; 74(1):44-51. PMID: 27434707.
      View in: PubMed
    37. Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017 03; 4(3):e122-e133. PMID: 27989576.
      View in: PubMed
    38. Achan J, Kakuru A, Ikilezi G, Mwangwa F, Plenty A, Charlebois E, Young S, Havlir D, Kamya M, Ruel T. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy. Pediatr Infect Dis J. 2016 Dec; 35(12):1329-1332. PMID: 27580060.
      View in: PubMed
    39. Brown LB, Havlir DV, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED. High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS. 2016 Nov 28; 30(18):2855-2864. PMID: 27603290.
      View in: PubMed
    40. Ssemmondo E, Mwangwa F, Kironde JL, Kwarisiima D, Clark TD, Marquez C, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G. Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):e46-e50. PMID: 27741032.
      View in: PubMed
    41. Chang W, Chamie G, Mwai D, Clark TD, Thirumurthy H, Charlebois ED, Petersen M, Kabami J, Ssemmondo E, Kadede K, Kwarisiima D, Sang N, Bukusi EA, Cohen CR, Kamya M, Havlir DV, Kahn JG. Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):e39-e45. PMID: 27741031.
      View in: PubMed
    42. Kakuru A, Natureeba P, Muhindo MK, Clark TD, Havlir DV, Cohan D, Dorsey G, Kamya MR, Ruel T. Malaria burden in a birth cohort of HIV-exposed uninfected Ugandan infants living in a high malaria transmission setting. Malar J. 2016 Oct 18; 15(1):500. PMID: 27756308.
      View in: PubMed
    43. Prahl M, Jagannathan P, McIntyre TI, Auma A, Farrington L, Wamala S, Nalubega M, Musinguzi K, Naluwu K, Sikyoma E, Budker R, Vance H, Odorizzi P, Nayebare P, Ategeka J, Kakuru A, Havlir DV, Kamya MR, Dorsey G, Feeney ME. Timing of in utero malaria exposure influences fetal CD4 T cell regulatory versus effector differentiation. Malar J. 2016 10 07; 15(1):497. PMID: 27717402.
      View in: PubMed
    44. Kadede K, Ruel T, Kabami J, Ssemmondo E, Sang N, Kwarisiima D, Bukusi E, Cohen CR, Liegler T, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G. Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS. 2016 Sep 10; 30(14):2121-6. PMID: 27258399.
      View in: PubMed
    45. Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, Charlebois E, Camlin C, Kahn J, Chang W, Glidden D, Kamya M, Havlir D, Geng E. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016 11; 3(11):e539-e548. PMID: 27658873.
      View in: PubMed
    46. Muhindo MK, Kakuru A, Natureeba P, Awori P, Olwoch P, Ategeka J, Nayebare P, Clark TD, Muehlenbachs A, Roh M, Mpeka B, Greenhouse B, Havlir DV, Kamya MR, Dorsey G, Jagannathan P. Reductions in malaria in pregnancy and adverse birth outcomes following indoor residual spraying of insecticide in Uganda. Malar J. 2016 Aug 26; 15(1):437. PMID: 27566109; PMCID: PMC5002129.
    47. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 09 01; 375(9):830-9. PMID: 27424812.
      View in: PubMed
    48. Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One. 2016; 11(7):e0158262. PMID: 27367521; PMCID: PMC4930205.
    49. Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med. 2016 07; 22(7):807-11. PMID: 27294875; PMCID: PMC5004598.
    50. Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, Ayieko J, Mwangwa F, Jain V, Byonanebye D, Petersen M, Havlir D, Kamya MR. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016; 11(5):e0156309. PMID: 27232186.
      View in: PubMed
    51. Havlir DV, Currier JS. CROI 2016: Complications of HIV Infection and Antiretroviral Therapy. Top Antivir Med. 2016 May-Jun; 24(1):38-46. PMID: 27398861.
      View in: PubMed
    52. Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda. Pediatr Infect Dis J. 2016 May; 35(5):524-9. PMID: 26771662; PMCID: PMC4829461 [Available on 05/01/17].
    53. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. N Engl J Med. 2016 Mar 10; 374(10):928-39. PMID: 26962728; PMCID: PMC4847718.
    54. Koss CA, Natureeba P, Nyafwono D, Plenty A, Mwesigwa J, Nzarubara B, Clark TD, Ruel TD, Achan J, Charlebois ED, Cohan D, Kamya MR, Havlir DV, Young SL. Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women. J Acquir Immune Defic Syndr. 2016 Mar 01; 71(3):310-5. PMID: 26397935; PMCID: PMC4752388.
    55. Katrak S, Day N, Ssemmondo E, Kwarisiima D, Midekisa A, Greenhouse B, Kamya M, Havlir D, Dorsey G. Community-wide Prevalence of Malaria Parasitemia in HIV-Infected and Uninfected Populations in a High-Transmission Setting in Uganda. J Infect Dis. 2016 Jun 15; 213(12):1971-8. PMID: 26908725; PMCID: PMC4878723 [Available on 06/15/17].
    56. Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016 May 01; 62(9):1081-8. PMID: 26839383; PMCID: PMC4826450 [Available on 05/01/17].
    57. Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016 Mar; 3(3):e111-9. PMID: 26939734; PMCID: PMC4780220 [Available on 03/01/17].
    58. Maeri I, El Ayadi A, Getahun M, Charlebois E, Akatukwasa C, Tumwebaze D, Itiakorit H, Owino L, Kwarisiima D, Ssemmondo E, Sang N, Kabami J, Clark TD, Petersen M, Cohen CR, Bukusi EA, Kamya M, Havlir D, Camlin CS. "How can I tell?" Consequences of HIV status disclosure among couples in eastern African communities in the context of an ongoing HIV "test-and-treat" trial. AIDS Care. 2016; 28 Suppl 3:59-66. PMID: 27421052.
      View in: PubMed
    59. Camlin CS, Ssemmondo E, Chamie G, El Ayadi AM, Kwarisiima D, Sang N, Kabami J, Charlebois E, Petersen M, Clark TD, Bukusi EA, Cohen CR, R Kamya M, Havlir D. Men "missing" from population-based HIV testing: insights from qualitative research. AIDS Care. 2016; 28 Suppl 3:67-73. PMID: 27421053.
      View in: PubMed
    60. Thirumurthy H, Jakubowski A, Camlin C, Kabami J, Ssemmondo E, Elly A, Mwai D, Clark T, Cohen C, Bukusi E, Kamya M, Petersen M, Havlir D, Charlebois ED. Expectations about future health and longevity in Kenyan and Ugandan communities receiving a universal test-and-treat intervention in the SEARCH trial. AIDS Care. 2016; 28 Suppl 3:90-8. PMID: 27421056.
      View in: PubMed
    61. Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda. PLoS One. 2015; 10(12):e0143433. PMID: 26632823; PMCID: PMC4669141.
    62. Young S, Natamba B, Luwedde F, Nyafwono D, Okia B, Osterbauer B, Natureeba P, Johnson L, Michel C, Zheng A, Robine M, Achan J, Charlebois E, Cohan D, Havlir D. "I Have Remained Strong Because of That Food": Acceptability and Use of Lipid-Based Nutrient Supplements Among Pregnant HIV-Infected Ugandan Women Receiving Combination Antiretroviral Therapy. AIDS Behav. 2015 Aug; 19(8):1535-47. PMID: 25416075; PMCID: PMC4441598.
    63. Havlir D, Gandhi M. Implementation challenges for long-acting antivirals as treatment. Curr Opin HIV AIDS. 2015 Jul; 10(4):282-9. PMID: 26049955.
      View in: PubMed
    64. Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015 Apr 24; 29(7):825-30. PMID: 25985404; PMCID: PMC4438773.
    65. Yukl SA, Shergill AK, Girling V, Li Q, Killian M, Epling L, Li P, Kaiser P, Haase A, Havlir DV, McQuaid K, Sinclair E, Wong JK. Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults. PLoS One. 2015; 10(3):e0121290. PMID: 25811360; PMCID: PMC4374729.
    66. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, Kozak B, Bloome J, Okiring J, Kakuru A, Bigira V, Kapisi J, Legac J, Gut J, Cooper RA, Kamya MR, Havlir DV, Dorsey G, Greenhouse B, Nsobya SL, Rosenthal PJ. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother. 2015; 59(6):3018-30. PMID: 25753626; PMCID: PMC4432194.
    67. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. PMID: 25742090; PMCID: PMC4351793.
    68. Havlir DV, Currier JS. CROI 2015: Complications of HIV Infection and Antiretroviral Therapy. Top Antivir Med. 2015 Mar-Apr; 23(1):56-65. PMID: 25965312.
      View in: PubMed
    69. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3. PMID: 25722197; PMCID: PMC4542662.
    70. Chamie G, Wandera B, Marquez C, Kato-Maeda M, Kamya MR, Havlir DV, Charlebois ED. Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health. 2015 Apr; 20(4):537-45. PMID: 25583212; PMCID: PMC4355181.
    71. Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015 Jan 14; 29(2):183-91. PMID: 25426808; PMCID: PMC4428759.
    72. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9. PMID: 25493596; PMCID: PMC4487368.
    73. Young SL, Plenty AH, Luwedde FA, Natamba BK, Natureeba P, Achan J, Mwesigwa J, Ruel TD, Ades V, Osterbauer B, Clark TD, Dorsey G, Charlebois ED, Kamya M, Havlir DV, Cohan DL. Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy. Matern Child Health J. 2014 Nov; 18(9):2044-53. PMID: 24585398; PMCID: PMC4419705.
    74. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Oct 01; 67(2):128-35. PMID: 25072616; PMCID: PMC4414017.
    75. Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/µl in rural Uganda. AIDS. 2014 Sep 24; 28(15):2241-9. PMID: 25022596; PMCID: PMC4894849.
    76. Marquez C, Davis JL, Katamba A, Haguma P, Ochom E, Ayakaka I, Chamie G, Dorsey G, Kamya MR, Charlebois E, Havlir DV, Cattamanchi A. Assessing the quality of tuberculosis evaluation for children with prolonged cough presenting to routine community health care settings in rural Uganda. PLoS One. 2014; 9(8):e105935. PMID: 25170875; PMCID: PMC4149493.
    77. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, Dorsey G, Rosenthal PJ. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One. 2014; 9(8):e105690. PMID: 25144768; PMCID: PMC4140830.
    78. Marquez C, Okiring J, Chamie G, Ruel TD, Achan J, Kakuru A, Kamya MR, Charlebois ED, Havlir DV, Dorsey G. Increased morbidity in early childhood among HIV-exposed uninfected children in Uganda is associated with breastfeeding duration. J Trop Pediatr. 2014 Dec; 60(6):434-41. PMID: 25145704; PMCID: PMC4303769.
    79. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689. PMID: 25093754; PMCID: PMC4122345.
    80. Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, Charlebois ED, Clark TD, Nzarubara B, Havlir DV, Achan J, Kamya MR, Cohan D, Dorsey G. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis. 2014 Dec 15; 210(12):1938-45. PMID: 24958908; PMCID: PMC4296178.
    81. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2014 May; 22(2):602-15. PMID: 24901886.
      View in: PubMed
    82. Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, Ruel T, Clark TD, Charlebois E, Rosenthal PJ, Havlir D, Kamya MR, Tappero JW, Dorsey G. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014 Aug 01; 59(3):446-53. PMID: 24759826; PMCID: PMC4155440.
    83. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):535-41. PMID: 24326597; PMCID: PMC3999287.
    84. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8. PMID: 24226057; PMCID: PMC3943693.
    85. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90. PMID: 24602844; PMCID: PMC4144040.
    86. Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):327-32. PMID: 24146022; PMCID: PMC4172444.
    87. Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr; 19(4):459-68. PMID: 24495307; PMCID: PMC4118739.
    88. Yukl SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS. 2014 Jan 28; 28(3):439-42. PMID: 24322272; PMCID: PMC4130176.
    89. Moyers BS, Secemsky EA, Vittinghoff E, Wong JK, Havlir DV, Hsue PY, Tseng ZH. Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus. Am J Cardiol. 2014 Apr 01; 113(7):1260-5. PMID: 24521717; PMCID: PMC3959566.
    90. Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9. PMID: 24430455; PMCID: PMC3993501.
    91. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014; 9(1):e84317. PMID: 24392124; PMCID: PMC3879307.
    92. Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013 Dec 09; 13:1151. PMID: 24321133; PMCID: PMC3890617.
    93. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 02; 382(9903):1525-33. PMID: 24152939; PMCID: PMC4058441.
    94. Vijayan T, Semitala FC, Matsiko N, Elyanu P, Namusobya J, Havlir DV, Kamya M, Geng EH. Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS. Clin Infect Dis. 2013 Dec; 57(12):1766-72. PMID: 24065326; PMCID: PMC3840406.
    95. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. PMID: 24038035; PMCID: PMC3933454.
    96. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):578-84. PMID: 24135775; PMCID: PMC3800282.
    97. Kim LH, Arinaitwe E, Nzarubara B, Kamya MR, Clark TD, Okong P, Charlebois ED, Havlir DV, Cohan D. Acceptability and feasibility of serial HIV antibody testing during pregnancy/postpartum and male partner testing in Tororo, Uganda. AIDS Care. 2014; 26(3):360-6. PMID: 23909832.
      View in: PubMed
    98. Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/µL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov; 57(9):1343-50. PMID: 23899683; PMCID: PMC3792723.
    99. Christopoulos KA, Havlir DV. Overcoming the human immunodeficiency virus obstacle course. JAMA Intern Med. 2013 Jul 22; 173(14):1344-5. PMID: 23778428.
      View in: PubMed
    100. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis. 2013 Oct 15; 208(8):1212-20. PMID: 23852128; PMCID: PMC3778964.
    101. Ades V, Mwesigwa J, Natureeba P, Clark TD, Plenty A, Charlebois E, Achan J, Kamya MR, Havlir DV, Cohan D, Ruel TD. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda. J Trop Pediatr. 2013 Dec; 59(6):441-6. PMID: 23764539; PMCID: PMC3842848.
    102. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange J, Lima VD, Patterson T, Strathdee SA, Williams B, Montaner J. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013 Apr 24; 27(7):1159-65. PMID: 23902921; PMCID: PMC4539010.
    103. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830; PMCID: PMC3719885.
    104. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013 Apr-May; 21(2):62-74. PMID: 23681961.
      View in: PubMed
    105. Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, Plenty A, Kakuru A, Achan J, Clark T, Osterbauer B, Kamya M, Havlir D. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):e101-3. PMID: 23924639; PMCID: PMC3738916.
    106. Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20; 27(4):627-34. PMID: 23169332; PMCID: PMC3809760.
    107. Ikilezi G, Achan J, Kakuru A, Ruel T, Charlebois E, Clark TD, Rosenthal PJ, Havlir D, Kamya MR, Dorsey G. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg. 2013 Apr; 88(4):744-6. PMID: 23358639; PMCID: PMC3617863.
    108. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605. PMID: 23243180; PMCID: PMC3552523.
    109. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8. PMID: 23190222; PMCID: PMC3664297.
    110. Tseng ZH, Moyers B, Secemsky EA, Havlir DV, Hsue PY. PR Interval and sudden cardiac death in patients with HIV infection. J Infect Dis. 2013 Jan 01; 207(1):199-200. PMID: 23186784; PMCID: PMC3523799.
    111. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012 Nov 13; 26(17):2121-33. PMID: 22695302; PMCID: PMC3819503.
    112. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):310-6. PMID: 22918158; PMCID: PMC3511816.
    113. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/µL in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7. PMID: 22955429; PMCID: PMC3501330.
    114. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400. PMID: 22916256; PMCID: PMC3423366.
    115. Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark T, Ades V, Plenty A, Charlebois E, Ruel T, Kamya M, Havlir D, Cohan D. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One. 2012; 7(8):e41934. PMID: 22879899; PMCID: PMC3413694.
    116. Havlir D, Beyrer C. The beginning of the end of AIDS? N Engl J Med. 2012 Aug 23; 367(8):685-7. PMID: 22809362.
      View in: PubMed
    117. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2012 Jun-Jul; 20(2):48-60. PMID: 22710907.
      View in: PubMed
    118. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012 May 22; 59(21):1891-6. PMID: 22595409; PMCID: PMC3356565.
    119. Riley ED, Neilands TB, Moore K, Cohen J, Bangsberg DR, Havlir D. Social, structural and behavioral determinants of overall health status in a cohort of homeless and unstably housed HIV-infected men. PLoS One. 2012; 7(4):e35207. PMID: 22558128.
      View in: PubMed
    120. Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, Rosenthal PJ, Dorsey G, Achan J, Akello C, Kamya MR, Wong JK. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis. 2012 Apr; 54(7):1001-9. PMID: 22308272; PMCID: PMC3297647.
    121. Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc. 2012; 15(2):17396. PMID: 22905358; PMCID: PMC3499795.
    122. Kamya MR, Byakika-Kibwika P, Gasasira AF, Havlir D, Rosenthal PJ, Dorsey G, Achan J. The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa. Future Virol. 2012; 7(7):699-708. PMID: 23293660.
      View in: PubMed
    123. Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011 Nov 28; 25(18):2269-78. PMID: 21941167; PMCID: PMC3572727.
    124. Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):e96-9. PMID: 22005002; PMCID: PMC4120944.
    125. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91. PMID: 22010914; PMCID: PMC3327101.
    126. Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011 Nov; 53(10):1008-14. PMID: 21960715; PMCID: PMC3193829.
    127. Kay J, Wanzira H, Sandison T, Kakuru A, Bigira V, Kamya M, Homsy J, Tappero JW, Havlir D, Dorsey G, Ruel T. Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda. J Trop Pediatr. 2012 Jun; 58(3):194-9. PMID: 21930666; PMCID: PMC3530275.
    128. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med. 2011 Nov 15; 184(10):1107-13. PMID: 21868507; PMCID: PMC3361323.
    129. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois ED, Feeney ME. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011 Sep; 53(6):592-9. PMID: 21840929; PMCID: PMC3160805.
    130. Dowdy DW, Geng EH, Christopoulos KA, Kahn JS, Hare CB, Wlodarczyk D, Havlir DV. Mortality among antiretroviral-eligible patients in an urban public clinic. J Acquir Immune Defic Syndr. 2011 Aug 01; 57(4):297-300. PMID: 21602697; PMCID: PMC3159809.
    131. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493-505. PMID: 21767103; PMCID: PMC3200068.
    132. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2011 May-Jun; 19(2):58-68. PMID: 21868823.
      View in: PubMed
    133. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods. 2011 Aug; 175(2):261-5. PMID: 21536073; PMCID: PMC3827908.
    134. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011 Apr 15; 52(8):1046-9. PMID: 21460322; PMCID: PMC3070031.
    135. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, Charlebois E, Havlir D, Mayanja-Kizza H, Whalen CC, Boom WH. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis. 2011 Apr 01; 203(7):992-1001. PMID: 21402550; PMCID: PMC3068037.
    136. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK, Achan J. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):44-50. PMID: 21099693; PMCID: PMC3078046.
    137. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, Akello C, Cao H, Dorsey G, Rosenthal PJ, Ssewanyana I, Kamya MR, Havlir DV. Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):330-5. PMID: 20592617; PMCID: PMC3025136.
    138. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010 Oct 23; 24(16):2451-60. PMID: 20827162; PMCID: PMC2997807.
    139. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010 Nov 15; 202(10):1553-61. PMID: 20939732; PMCID: PMC2997806.
    140. Li P, Ruel T, Fujimoto K, Hatano H, Yukl S, Eller LA, Liegler T, Kamya M, Gassasira A, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK. Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes. J Virol Methods. 2010 Dec; 170(1-2):115-20. PMID: 20863855; PMCID: PMC3280821.
    141. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010 Sep 01; 202(5):705-16. PMID: 20662716; PMCID: PMC2916952.
    142. Charlebois ED, Havlir DV. "A bird in the hand...": a commentary on the test and treat approach for HIV. Arch Intern Med. 2010 Aug 09; 170(15):1354-6. PMID: 20696961.
      View in: PubMed
    143. Chamie G, Charlebois ED, Srikantiah P, Walusimbi-Nanteza M, Mugerwa RD, Mayanja H, Okwera A, Whalen CC, Havlir DV. Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis. 2010 Aug 01; 51(3):359-62. PMID: 20569064; PMCID: PMC2919368.
    144. Bebell LM, Pilcher CD, Dorsey G, Havlir D, Kamya MR, Busch MP, Dunn Williams J, Nugent CT, Bentsen C, Rosenthal PJ, Charlebois ED. Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS. 2010 Jul 31; 24(12):1945-52. PMID: 20543656; PMCID: PMC2909782.
    145. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, Ruel T, Kateera F, Meya DN, Havlir D, Rosenthal PJ, Dorsey G. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010 Jun 23; 9:177. PMID: 20573194; PMCID: PMC2903607.
    146. Boivin MJ, Ruel TD, Boal HE, Bangirana P, Cao H, Eller LA, Charlebois E, Havlir DV, Kamya MR, Achan J, Akello C, Wong JK. HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS. 2010 May 15; 24(8):1163-70. PMID: 20425886; PMCID: PMC2880483.
    147. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S245-54. PMID: 20397955; PMCID: PMC3032796.
    148. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral treatment. Top HIV Med. 2010 Apr-May; 18(2):57-65. PMID: 20516525; PMCID: PMC3032798.
    149. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One. 2010 Feb 22; 5(2):e9138. PMID: 20179751; PMCID: PMC2825253.
    150. Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, Havlir D, Rosenthal PJ, Dorsey G, Clark TD, Cohan D. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J. 2009 Nov 14; 8:254. PMID: 19912657; PMCID: PMC2781026.
    151. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):424-9. PMID: 19506482.
      View in: PubMed
    152. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009 Jun 01; 23(9):1109-18. PMID: 19417580; PMCID: PMC2739977.
    153. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2009 Apr-May; 17(2):57-67. PMID: 19401608.
      View in: PubMed
    154. Getahun H, Havlir D, Granich R, Reid A, Jaramillo E, Nunn P. Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now. Trop Med Int Health. 2009 Apr; 14(4):376-8. PMID: 19302631.
      View in: PubMed
    155. Ruel T, Ssewanyana I, Achan J, Gasasira A, Kamya MR, Kekitiinwa A, Wong JK, Cao H, Havlir D, Charlebois ED. Dynamics of T cell activation accompanying CD4 recovery in antiretroviral treated HIV-infected Ugandan children. Clin Immunol. 2009 Jun; 131(3):410-4. PMID: 19303366; PMCID: PMC3032795.
    156. Davis JL, Huang L, Kovacs JA, Masur H, Murray P, Havlir DV, Worodria WO, Charlebois ED, Srikantiah P, Cattamanchi A, Huber C, Shea YR, Chow Y, Fischer SH. Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis. Clin Infect Dis. 2009 Mar 15; 48(6):725-32. PMID: 19207077; PMCID: PMC2657807.
    157. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Günthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology. 2009 Apr 25; 387(1):98-108. PMID: 19268337; PMCID: PMC4474533.
    158. Ssewanyana I, Baker CA, Ruel T, Bousheri S, Kamya M, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Cao H. The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda. AIDS Res Hum Retroviruses. 2009 Jan; 25(1):65-71. PMID: 19182922; PMCID: PMC2858297.
    159. Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, Kayanja HK, Mugerwa RD, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):458-60. PMID: 19011423; PMCID: PMC4752197.
    160. Chakaya J, Getahun H, Granich R, Havlir D. Confronting TB/HIV in the era of increasing anti-TB drug resistance. J Int AIDS Soc. 2008 Nov 06; 11:6. PMID: 19014421; PMCID: PMC2588552.
    161. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 01; 47(3):421-4. PMID: 18558886; PMCID: PMC2586907.
    162. Havlir DV. HIV integrase inhibitors--out of the pipeline and into the clinic. N Engl J Med. 2008 Jul 24; 359(4):416-8. PMID: 18650518.
      View in: PubMed
    163. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30. PMID: 18647985.
      View in: PubMed
    164. Ruel TD, Achan J, Gasasira AF, Charlebois ED, Mehbratu T, Rosenthal PJ, Dorsey G, Kamya MR, Kekitiinwa A, Wong J, Havlir DV. HIV RNA suppression among HIV-infected Ugandan children with measles. J Acquir Immune Defic Syndr. 2008 Jun 01; 48(2):225-7. PMID: 18520684; PMCID: PMC3040680.
    165. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15; 358(20):2095-106. PMID: 18480202; PMCID: PMC3885902.
    166. Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, Charlebois E, Staedke SG, Kekitiinwa A, Rosenthal PJ, Havlir D, Dorsey G. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008 Apr 01; 46(7):985-91. PMID: 18444813.
      View in: PubMed
    167. Currier JS, Havlir DV. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Complications of HIV disease and therapy. Top HIV Med. 2008 Apr-May; 16(1):23-30. PMID: 18441380.
      View in: PubMed
    168. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008 Feb 01; 197(3):411-9. PMID: 18248304.
      View in: PubMed
    169. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007 Dec 15; 45(12):1633-9. PMID: 18190326.
      View in: PubMed
    170. Bebell LM, Gasasira A, Kiggundu M, Dokomajilar C, Kamya MR, Charlebois ED, Havlir D, Rosenthal PJ, Dorsey G. HIV-1 infection in patients referred for malaria blood smears at government health clinics in Uganda. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):624-30. PMID: 18043317.
      View in: PubMed
    171. Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG, Gasasira A, Kamya M, Nakiwala J, Achan J, Charlebois E, Havlir D, Cao H. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis. 2007 Dec 01; 196(11):1667-70. PMID: 18008251.
      View in: PubMed
    172. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, Charlebois ED, Rosenthal PJ, Havlir D, Dorsey G. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007 Oct 01; 21(15):2059-66. PMID: 17885296.
      View in: PubMed
    173. Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS. 2007 Sep 12; 21(14):1972-4. PMID: 17721107; PMCID: PMC4752198.
    174. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis. 2007 Aug 15; 196 Suppl 1:S46-51. PMID: 17624825.
      View in: PubMed
    175. Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials. 2007 Jul-Aug; 8(4):193-204. PMID: 17720659.
      View in: PubMed
    176. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007 May 15; 195(10):1426-36. PMID: 17436222.
      View in: PubMed
    177. Currier JS, Havlir DV. Complications of HIV disease and therapy. Top HIV Med. 2007 Apr-May; 15(2):40-7. PMID: 17485786.
      View in: PubMed
    178. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15; 44(6):889-91. PMID: 17304470.
      View in: PubMed
    179. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007 Apr 01; 175(7):737-42. PMID: 17218620; PMCID: PMC1899289.
    180. Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006 Nov 01; 194(9):1309-18. PMID: 17041858.
      View in: PubMed
    181. Gasasira AF, Dorsey G, Kamya MR, Havlir D, Kiggundu M, Rosenthal PJ, Charlebois ED. False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol. 2006 Aug; 44(8):3021-4. PMID: 16891532; PMCID: PMC1594619.
    182. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med. 2006 Jul 13; 355(2):173-81. PMID: 16837681.
      View in: PubMed
    183. Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV. Antiretroviral therapy and TB. Trop Doct. 2006 Apr; 36(2):73-9. PMID: 16611437.
      View in: PubMed
    184. Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2006 Mar-Apr; 14(1):27-35. PMID: 16641525.
      View in: PubMed
    185. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 01; 41(1):31-6. PMID: 16340470; PMCID: PMC4050666.
    186. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006 Jan 01; 193(1):9-15. PMID: 16323126.
      View in: PubMed
    187. Havlir DV, Hammer SM. Patents versus patients? Antiretroviral therapy in India. N Engl J Med. 2005 Aug 25; 353(8):749-51. PMID: 16120852.
      View in: PubMed
    188. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 2005 Jul; 49(7):2983-5. PMID: 15980379.
      View in: PubMed
    189. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005 May 01; 191(9):1410-8. PMID: 15809898.
      View in: PubMed
    190. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2005 Mar-Apr; 13(1):16-23. PMID: 15849369.
      View in: PubMed
    191. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, Miller MD, Wong JK. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis. 2005 Apr 01; 191(7):1164-8. PMID: 15747253.
      View in: PubMed
    192. Srikantiah P, Charlebois E, Havlir DV. Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics. J Infect Dis. 2005 Jan 15; 191(2):147-9. PMID: 15609222.
      View in: PubMed
    193. Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004 Dec 01; 39(11):1699-704. PMID: 15578373.
      View in: PubMed
    194. Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 01; 38(11):1599-604. PMID: 15156449.
      View in: PubMed
    195. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Top HIV Med. 2004 Mar-Apr; 12(1):31-45. PMID: 15111728.
      View in: PubMed
    196. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003 Nov 07; 17(16):2345-9. PMID: 14571186.
      View in: PubMed
    197. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, Wong JK. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003 Oct; 77(20):11212-9. PMID: 14512569; PMCID: PMC224988.
    198. Havlir DV. Strategic approaches to antiretroviral treatment. Top HIV Med. 2003 Jul-Aug; 11(4):145-9. PMID: 12876333.
      View in: PubMed
    199. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med. 2003 Jun 05; 348(23):2279-81. PMID: 12788990.
      View in: PubMed
    200. Havlir DV, Currier JS. Complications of HIV infection and antiretroviral therapy. Top HIV Med. 2003 May-Jun; 11(3):86-91. PMID: 12837967.
      View in: PubMed
    201. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002 Dec; 46(12):3907-16. PMID: 12435695; PMCID: PMC132776.
    202. Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob Agents Chemother. 2002 Dec; 46(12):3877-82. PMID: 12435691; PMCID: PMC132738.
    203. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):20-6. PMID: 12352146.
      View in: PubMed
    204. Jones D, Havlir DV. Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med. 2002 Sep; 23(3):665-74. PMID: 12371002.
      View in: PubMed
    205. Havlir D, Vella S, Hammer S. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. AIDS. 2002 Jul 05; 16(10):7-9. PMID: 12146462.
      View in: PubMed
    206. Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses. 2002 Jul 01; 18(10):699-704. PMID: 12167276.
      View in: PubMed
    207. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002 Apr; 8(4):379-85. PMID: 11927944.
      View in: PubMed
    208. Hogg RS, Havlir D, Miller V, Montaner JS. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002 Mar 29; 16(5):787-9. PMID: 11964536.
      View in: PubMed
    209. Appay V, Hansasuta P, Sutton J, Schrier RD, Wong JK, Furtado M, Havlir DV, Wolinsky SM, McMichael AJ, Richman DD, Rowland-Jones SL, Spina CA. Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS. 2002 Jan 25; 16(2):161-70. PMID: 11807299.
      View in: PubMed
    210. Havlir DV. Structured intermittent treatment for HIV disease: Necessary concession or premature compromise? Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):4-6. PMID: 11782542; PMCID: PMC117502.
    211. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu TM, Emini EA, Shiver JW. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol. 2002 Jan; 76(1):185-94. PMID: 11739684; PMCID: PMC135696.
    Diane's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _